WHO approves emergency use of Covovax vaccine
The World Health Organization (WHO) has approved the Covovax coronavirus vaccine for emergency use, which is manufactured by the Serum Institute of India under license from the American company Novavax, the WHO said in a statement, Report informs citing RIA Novosti.
“Today, the World Health Organization issued and emergency use listing (EUL) for NVX-CoV2373, expanding the basket of WHO-validated vaccines against the SARS-CoV-2 virus. The vaccine, named CovovaxTM, is produced by the Serum Institute of India under license from Novavax and is part of the COVAX facility portfolio, giving a much-needed boost to ongoing efforts to vaccinate more people in lower-income countries,” the press release reads.
WHO’s EUL procedure assesses the quality, safety, and efficacy of COVID-19 vaccines and is a prerequisite for COVAX vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.